Definitive Contract HHSN261201200038C
Award Date 9/28/12
Potential Completion Date 9/27/14
Potential Value $1.2M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Raleigh, NC 27615, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...
- <p>This contract was awarded by the National Cancer Institute, a civilian agency, to Nanoparticle Biochem, Inc., a for-profit organization and manufacturer of goods. The $998,293.57 cost-plus-fixed-fee contract is for the development of in vivo compatible and readily injectable gold nanoconstructs for tumor therapy. The contract was set aside for a small business and has an ultimate completion date of August 26, 2015.</p>
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of "functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles" for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaco-Kinesis Corporation, a small business, for a Phase I project entitled "A VEGF Nanosensor to Monitor Tumor Progression". The contract has a ceiling value of $170,009.00 and an ultimate completion date of August 27, 2013. The contract was awarded on September 28, 2012 under the "Other Functions Topic 301" solicitation. No additional details about subcontractors...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biocure Inc. for the development of "Targeted Multifunctional Polymersomes for Cancer Therapy". The contract is a Firm Fixed Price Definitive Contract with a ceiling value of $199,889. The period of performance is from the award date of September 30, 2009 to the ultimate completion date of July 31, 2010. This SBIR Phase I contract is focused on...
- <p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
- The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI) awarded a purchase order contract valued at one hundred twenty thousand six hundred dollars ($120,600) to Vector Biomed Inc. The contract is to obtain preclinical grade lentiviral vectors in support of NCI's Pediatric Oncology Branch investigational new drug enabling studies and demonstration of clinical-grade vector production feasibility. Services include receipt confirmation...
- <p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>